Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2002 June;46(2) > The Quarterly Journal of Nuclear Medicine 2002 June;46(2):131-7

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEW ARTICLES  THE REPRODUCTIVE SYSTEM
Guest Editors: Freeman L. M., Bombardieri E.


The Quarterly Journal of Nuclear Medicine 2002 June;46(2):131-7

language: English

The role of 111In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer

Freeman L. M., Krynyckyi B. R., Li, Y., Korupulu G., Saleemi K., Haseman M. K. *, Kahn D. **

Depart­ment of ­Nuclear Med­i­cine Mon­tef­iore Med­ical ­Center and Albert Ein­stein Col­lege of Med­i­cine Bronx, New ­York, USA
* Sutter Com­mu­nity Hos­pital ,Sac­ra­mento, CA, USA
** Jowa ­City Vet­e­rans Admin­is­tra­tion, Med­ical ­Center Jowa ­City, IA, USA


FULL TEXT  


111In Cap­romab Pende­tide (Pros­taS­cintR) is a ­whole ­murine anti­body ­that is reac­tive ­with pros­tate spe­cific mem­brane ­antigen (­PSMA), a gly­co­pro­tein on the sur­face of ­normal and ­abnormal pros­tate epi­the­lium. It has ­proven to be of ­great ­value in ­assisting man­age­ment deci­sions in pros­tate ­cancer ­patients who ­initially ­present ­with ­high ­risk for met­a­static ­spread, or who ­develop a pic­ture of recur­rent dis­ease ­after sur­gery or radi­a­tion ­therapy. Pat­terns of met­a­static lym­phatic ­spread ­have cor­re­lated ­well ­with ­autopsy ­reports in the lit­er­a­ture. Unfor­tu­nately, ­other ­imaging ­study and/or his­to­logic con­fir­ma­tion of scin­ti­graphic find­ings has ­been dif­fi­cult to ­obtain. ­Prostascint’s ­role in pre­dicting dur­able com­plete ­response (DCR) in post­op­er­a­tive ­patients ­having sal­vage radio­therapy to ­their pros­tate ­fossa is ­very prom­ising. Fur­ther inves­ti­ga­tive ­work in ­larger ­patient pop­u­la­tions is ­needed to con­firm ­these ­early ­results.

top of page

Publication History

Cite this article as

Corresponding author e-mail